الفرق بين المراجعتين لصفحة: «ساكساغلبتين»

من موسوعة العلوم العربية
اذهب إلى التنقل اذهب إلى البحث
(نقل النص للترجمة)
(لا فرق)

مراجعة 13:23، 26 مارس 2013

ساكساغلبتين
Systematic (IUPAC) name
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)
acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a610003
Licence data EMA:Link, US FDA:link
Pregnancy cat. ?
Legal status POM (UK) ℞-only (US)
Routes Oral
Identifiers
CAS number 361442-04-8 N
ATC code A10BH03
PubChem CID 11243969
DrugBank DB06335
ChemSpider 9419005 YesY
UNII 8I7IO46IVQ N
ChEMBL CHEMBL385517 YesY
Chemical data
Formula C18H25N3O2 
Mol. mass 315.41 g/mol
 N (what is this?)  (verify)

Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.[1] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5–100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period.[2] In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.[3]

The FDA approved Saxagliptin with brand name Onglyza on July 31, 2009.[4]

Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP[5] and the degradation of GLP-1.[5][6]

Bristol-Myers Squibb announced on 27 December 2006 that Otsuka Pharmaceutical Co. has been granted exclusive rights to develop and commercialize the compound in Japan. Under the licensing agreement, Otsuka will be responsible for all development costs, but Bristol-Myers Squibb retains rights to co-promote saxagliptin with Otsuka in Japan.[7] Further, on 11 January 2007 it was announced that Bristol-Myers Squibb and AstraZeneca would work together to complete development of the drug and in subsequent marketing.[8]

التصنيع

The synthesis of Saxagliptin by Bristol-Myers Squibb by the amide coupling of N-Boc-3-hydroxyadamantylglycine (2) and methanoprolineamide (3) with EDC. The former is commercially available, whereas the latter is available as the N-Boc analog. The prolineamide moiety is subsequently dehydrated with trifluoroacetic anhydride to give the cyanide as the trifluoracetate ester, which is hydrolyzed. Removal of the Boc protecting group, followed by neutralization gives the desired product (1):[9]

Production of saxagliptin.png

التأثير الدوائي

Saxagliptin is part of a class of diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones. As a DPP-4 inhibitor, Saxagliptin slows down the breakdown of incretin hormones, increasing the level of these hormones in the body. It is this increase in incretin hormones that is responsible for the beneficial actions of Saxagliptin, including increasing insulin production in response to meals and decreasing the amount of glucose (sugar) that the liver produces.[10]

Because incretin hormones are more active in response to higher blood sugar levels (and are less active in response to low blood sugar), the risk of dangerously low blood sugar (hypoglycemia) is low with Saxagliptin.

فعالية

Oral saxagliptin 2.5 or 5 mg once daily suppresses DPP-4 activity for 24 hours,[11] significantly improving mean HbA1c levels (relative to placebo) in well designed, 24-week trials in treatment-naive patients with type 2 diabetes.[12] Combination therapy with saxagliptin 5 mg once daily and metformin was more effective than saxagliptin or metformin monotherapy.[12] When the relative benefits of increasing the dose of a sulfonylurea or adding saxagliptin were assessed in a study of 768 patients, combination treatments were shown to have a significantly greater impact on fasting blood glucose than increasing the tested glibenclamide dose alone.[11]

أمان الدواء

In 4148 patients studied, 3 adverse reactions were seen higher in saxaglyptin vs placebo. Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo.[13]

Number (%) of Patients
ONGLYZA 5 mg N=882 Placebo N=799
Upper respiratory tract infection 68 (7.7) 61 (7.6)
Urinary tract infection 60 (6.8) 49 (6.1)
Headache 57 (6.5) 47 (5.9)[13]
  • The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.[13]

In February 2012, Bristol-Myers/Astra Zeneca distributed additional safety information on saxaglyptin use in South Africa. The package insert is to be edited for South Africa. Contra-indications will now include a history of sensitivity to saxaglyptin (or an other DPP4 inhibitor) as well as pancreatitis. Spontaneously-reported adverse events in South Africa have included anaphylaxis, angioedema and acute pancreatitis.

تحمل الدواء

Both monotherapy and combination therapy with other agents was generally well tolerated in clinical trials.[12]

خطر الإصابة بالسرطان مع مثبطات PP-4

The DPP-4 enzyme is known to be involved in the suppression of certain malignancies, particularly in limiting the tissue invasion of these tumours. Inhibiting the DPP-4 enzymes may allow some cancers to progress.[14][15] A study of DPP-4 inhibition in human non-small cell lung cancer (NSCLC) concluded that "DPPIV functions as a tumor suppressor, and its downregulation may contribute to the loss of growth control in NSCLC cells.[16]

The risk of cancer suppression with DPP-4 down-regulation applies to all the DPP-4 inhibitors on the market in addition to saxagliptin (sitagliptin and vildagliptin)

انظر أيضاً

المصادر

  1. ↑ Augeri D; et al. (2005). "Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes". Journal of Medicinal Chemistry. 48 (15): 5025–5037. PMID 16033281. doi:10.1021/jm050261p. 
  2. ↑ Robert Frederich, MD, PhD; et al. (2010). "A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes". Postgraduate Medicine. 122 (3): 16–27. PMID 20463410. doi:10.3810/pgm.2010.05.2138.  Unknown parameter |month= ignored (|date= suggested) (help)
  3. ↑ "Bristol, Takeda Drugs Offer Alternatives to Januvia (Update2)". Bloomberg. 2008-06-07. 
  4. ↑ Telegram (2 August 2009). "FDA approves diabetes drug from two area manufacturers". Worcester Telegram & Gazette Corp. Retrieved 2009-08-02. 
  5. ↑ 5٫0 5٫1 Mentlein, R; Gallwitz, B; Schmidt, WE (15 June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum". European Journal of Biochemistry. 214 (3): 829–835. PMID 8100523. doi:10.1111/j.1432-1033.1993.tb17986.x.  Cite uses deprecated parameter |coauthors= (help);
  6. ↑ Ahrén, Bo; Landin-Olsson, Mona; Jansson, Per-Anders; Svensson, Maria; Holmes, David; Schweizer, Anja (2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes". Journal of Clinical Endocrinology & Metabolism. 89 (5): 2078–2084. PMID 15126524. doi:10.1210/jc.2003-031907. Retrieved 2007-01-11.  Unknown parameter |month= ignored (|date= suggested) (help); Cite uses deprecated parameter |coauthors= (help)
  7. ↑ Bristol-Myers Squibb(December 27, 2006). "Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan". بيان صحفي. وصل إليه في 2006-12-27.
  8. ↑ Associated Press (11 January 2007). "AstraZeneca teams with Bristol-Myers on diabetes drugs". Delaware News-Journal. Retrieved 2007-01-11. [وصلة مكسورة]
  9. ↑ Savage, Scott A.; Jones, Gregory S.; Kolotuchin, Sergei; Ramrattan, Shelly Ann; Vu, Truc; Waltermire, Robert E.; Scott A. Savage, Gregory S. Jones, Sergei Kolotuchin, Shelly Ann Ramrattan, Truc Vu, and Robert E. Waltermire (2009). "Preparation of Saxagliptin, a Novel DPP-IV Inhibitor". Org. Process Res. Dev. 13: 091016152805096. doi:10.1021/op900226j.  Missing |last7= in Authors list (help)
  10. ↑ [1] Diabetes info
  11. ↑ 11٫0 11٫1 "New Drugs: Saxagliptin". Australian Prescriber (34): 89–91. 2011.  Unknown parameter |month= ignored (|date= suggested) (help)
  12. ↑ 12٫0 12٫1 12٫2 Dhillon, S; Weber, J. (2009). "Saxagliptin". Drugs. 69 (15): 2103–2114. PMID 19791828. doi:10.2165/11201170-000000000-00000. 
  13. ↑ 13٫0 13٫1 13٫2 "Onglyza". RxList. Retrieved 2012-01-31. 
  14. ↑ Pro B, Dang NH (2004). "CD26/dipeptidyl peptidase IV and its role in cancer". Histol. Histopathol. 19 (4): 1345–51. PMID 15375776.  Unknown parameter |month= ignored (|date= suggested) (help)
  15. ↑ Wesley UV, McGroarty M, Homoyouni A (2005). "Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway". Cancer Res. 65 (4): 1325–34. PMID 15735018. doi:10.1158/0008-5472.CAN-04-1852.  Unknown parameter |month= ignored (|date= suggested) (help)
  16. ↑ Wesley, U; et al (2004). "Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.". Int J Cancer. 109 (6): 855–866. PMID 15027119. doi:10.1002/ijc.20091.  Cite uses deprecated parameter |coauthors= (help)

روابط خارجية

مجلوبة من «http://www.arabsciencepedia.org/w/index.php?title=ساكساغلبتين&oldid=24762»